The goal of the UNC SPORE is to reduce breast cancer mortality and incidence in North Carolina through an interdisciplinary program of research and intervention that: 1. Integrates efforts in cancer prevention and control, molecular epidemiology, clinical research, and laboratory sciences; and 2. Targets behavioral and biologic issues relevant to African American women. The six primary objectives of the UNC SPORE are to: 1. Identify the determinants of the Black/White gap in breast cancer mortality in North Carolina, and then to use novel community and provider interventions to increase early detection and eliminate the gap; 2. Initiate a long-term, population-based study of breast cancer etiology in a defined North Carolina population containing 630,000 women aged 20- 74, 29% of whom are African American; 3. Combine molecular biology and epidemiology in the investigation of the environmental and genetic determinants to breast cancer in African American and White women in the defined population; 4. Develop new clinical markers for neoplastic proliferation of breast cancer cells through the discovery of new genes: 5. Promote new translational research projects and recruit new investigators to breast cancer research; and 6. Complement the NCI and other SPOREs in the national effort to reduce breast cancer mortality and incidence by focusing in on minority issues, development and use of novel molecular epidemiologic approaches, and the development of public health research programs in breast cancer and control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-06
Application #
2458083
Study Section
Special Emphasis Panel (SRC (27))
Project Start
1992-09-30
Project End
2000-07-31
Budget Start
1997-08-05
Budget End
1998-07-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386

Showing the most recent 10 out of 598 publications